Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Overview
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development
Accure Therapeutics SL
Aquilus Pharmaceuticals Inc
AstraZeneca Plc
EA Pharma Co Ltd
Elastomics AB
Iproteos SL
MabTrix Ltd
Pharmahungary Group
Pikralida Sp zoo
Proteris Biotech Inc
Releviate Therapeutics
Shulov Innovative Science Ltd
Translatiol Sciences Inc
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Drug Profiles
ACT-03 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AQU-118 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZD-1236 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CALY-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IPRO-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-9i - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclol Antibody to Inhibit MMP9 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
ND-336 - Drug Profile
Product Description
Mechanism Of Action
PKL-021 - Drug Profile
Product Description
Mechanism Of Action
Protearin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombint MMP-9 Replacement for Liver Fibrosis, Pulmory Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
Recombint Protein to Target MMP-9 for Wounds - Drug Profile
Product Description
Mechanism Of Action
RLVT-903 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Matrix Metalloproteise 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target MMP2 and MMP9 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Dormant Products
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Discontinued Products
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Product Development Milestones
Featured News & Press Releases
May 20, 2022: Birmingham research brings hope for spil cord injury treatment
Jul 12, 2021: Co-fincing from 3/1.1.1/2020 fast track for Mazovia competition
Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Accure Therapeutics SL, 2022
Pipeline by Aquilus Pharmaceuticals Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by EA Pharma Co Ltd, 2022
Pipeline by Elastomics AB, 2022
Pipeline by Iproteos SL, 2022
Pipeline by MabTrix Ltd, 2022
Pipeline by Pharmahungary Group, 2022
Pipeline by Pikralida Sp zoo, 2022
Pipeline by Proteris Biotech Inc, 2022
Pipeline by Releviate Therapeutics, 2022
Pipeline by Shulov Innovative Science Ltd, 2022
Pipeline by Translational Sciences Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022